Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Has Consensus Target Price of $13.08

Posted by Brian Himes on Oct 5th, 2026

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) have been given an average rating of “Moderate Buy” by the nine analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $13.08.

VNDA has been the topic of several research analyst reports. HC Wainwright lowered their price objective on shares of Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. B. Riley Financial restated a “buy” rating and issued a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Finally, Oppenheimer began coverage on Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price target on the stock.

Check Out Our Latest Report on Vanda Pharmaceuticals

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA opened at $4.63 on Friday. Vanda Pharmaceuticals has a 12 month low of $4.27 and a 12 month high of $9.94. The firm has a market capitalization of $279.93 million, a PE ratio of -1.00 and a beta of 0.69. The company’s 50 day simple moving average is $5.19 and its 200 day simple moving average is $6.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.61 and a quick ratio of 1.60.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.46). The firm had revenue of $50.53 million for the quarter, compared to the consensus estimate of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. As a group, equities research analysts forecast that Vanda Pharmaceuticals will post -3.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. State Street Corp raised its position in shares of Vanda Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after purchasing an additional 500,843 shares during the period. Syon Capital LLC acquired a new position in Vanda Pharmaceuticals during the 2nd quarter worth $125,000. Hsbc Holdings PLC boosted its holdings in Vanda Pharmaceuticals by 144.5% during the second quarter. Hsbc Holdings PLC now owns 94,988 shares of the biopharmaceutical company’s stock valued at $579,000 after acquiring an additional 56,133 shares during the period. Wellington Management Group LLP bought a new stake in Vanda Pharmaceuticals during the second quarter valued at about $220,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at about $749,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company was founded in 2003 and is headquartered in Washington, DC Its work centers on conditions involving sleep, circadian rhythms, and psychiatric health.

Vanda’s commercial products include Hetlioz (tasimelteon), a melatonin receptor agonist approved in the United States for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults.